|Articles|January 21, 2021

EMA Publishes Human Medicines: Highlights of 2020

EMA has published an overview of its key recommendations in 2020 on the authorization and safety monitoring of medicines for human use.

In 2020, EMA recommended 97 medicines for marketing authorization. Of these, 39 had a new active substance which had never been authorized in the European Union before. The Agency recommended one vaccine and one treatment for COVID-19. The infographic includes figures on the authorization of medicines and a selection of new treatments that represent significant progress in their therapeutic areas.

For more information, click here.

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Related to this article

October 16th, 2026

Building Trust Into Oncology Real-World Evidence: Q&A with Saamir Pasha and Carole Berini, Ontada

In this Q&A, Saamir Pasha and Carole Berini, PhD, of Ontada discuss what it takes to harmonize fragmented oncology data into reliable real-world evidence, how lab markers can proxy for missing functional status data, and where the biggest remaining barriers to consistent RWE generation lie.

October 12th, 2026

What a Practical Roadmap for FDA and EMA Quality Frameworks Actually Looks Like

In this video interview, Saamir Pasha and Carole Berini, PhD, of Ontada, describe what operationalizing regulatory-grade quality frameworks requires—and why fit-for-purpose evidence generation is a transparency and documentation discipline, not just a data cleanliness exercise.

October 22nd, 2026

Bipartisan Bill Would Build Reusable Clinical Trial Networks, With a Focus on Rare Disease

The Faster Clinical Trials Act would create an FDA Center for Clinical Trial Innovation and aims to cut trial costs and enrollment time by at least 30%.

© photon_photo - © photon_photo - stock.adobe.com

October 22nd, 2026

Building Standardized Evidence for eSource-Enabled Clinical Trials: Multi-Site Validation of a Clinical Research Coordinator Satisfaction Methodology

Standardized measurement across five oncology centers found that clinical research coordinators rated eSource-enabled workflows positively (Overall Mean Satisfaction 5.79 of 7), with reduced manual entry and electronic data transfer earning strong marks, while perceived reduction in sponsor and monitor queries lagged as the one domain below threshold.

October 22nd, 2026

Where the Industry Is Headed as Clinical, Operational, and Real-World Data Connect

In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, describes the industry’s trajectory toward a unified intelligence orchestration environment—and explains why the future isn’t one model that knows everything, but a trusted system that brings the right evidence to the right human decision.

October 22nd, 2026

ACT Brief: Applied Clinical Trials at 2026 SCRS Global Site Solutions Summit

In today’s ACT Brief, we examine how sites can avoid both fear-driven and overly aggressive AI adoption, why community-based research needs sustained financial investment, and why patient access matters more than organizational size.

© putilov_denis - © putilov_denis - stock.adobe.com

October 21st, 2026

Obesity Is More Than Weight: Practical Approaches to Managing Comorbidities in Clinical Research

Pacing obesity trial enrollment, anchoring eligibility to stable real-world therapies, and building site and physician relationships improve retention and data quality more than aggressive recruitment or restrictive exclusion criteria do.

October 21st, 2026

What Expanding AI Ecosystems Mean for Sponsor Complexity and Oversight

In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, argues that CROs must act as orchestrators rather than aggregators—and that the real test of any AI ecosystem is whether it reduces sponsor coordination burden or just hands it back to them.